| RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity |
Ongoing |
Ranibizumab |
3 |
CRFB002H2301 V 01 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Phase 2 study of 5 Days azacytidine priming prior to fludarabine, cytarabine and G-CSF combination for patients with relapsed or refractory AML. |
Ongoing |
Vidaza |
2 |
Version 1.1 |
King Fahad Medical City (Riyadh) |
| An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) |
Terminated |
NIVOLUMAB/IPILIMUMAb |
3 |
CA209-227 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Asia and Latin America Fracture Observational Study |
Ongoing |
Forteo (teriparatide) |
4 |
B3D-MC-B02 |
King Fahad Medical City (Riyadh), Al-Noor Specialist Hospital, King Fahad Hospital (Jeddah), Sabia General Hospital, King Saud Medical City (Riyadh), King Fahad University Hospital (Al-Khobar) |
| "A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety ofAbatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naive" |
Terminated |
Abatacept |
3b |
IM101550 |
King Fahad Medical City (Riyadh) |
| An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents from 5 to less than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) |
Rejected |
Mirabegron |
3 |
178-CL-206A |
N\A |
| "randomised, multicentre, double-blind, placebo-controlledstudy of ambrisentan in subjects with inoperable chronicthromboembolic pulmonary hypertension (CTEPH)" |
Terminated |
Ambrisentan 5 mg |
3 |
AMB115811 |
N\A |
| Prospective, Randomized, open label Controlled trial to evaluate the safety and efficacy of Dexmedetomidine Compared with Midazolam in children admitted to Pediatric Critical Care unit (PICU) at KAMC-NGHA (PROMISE) |
Rejected |
Dexmedetomidine |
3 |
RC11/084 |
N\A |
| A randomized, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GWP42003: GWP42004 plus GWP42003 and GWP42004 alone in the treatment of dyslipedemia in subjects with Type 2 diabetes. |
Rejected |
Cannabidiol & Tetrahydrocannabivarin |
2a |
GWZMD1190 |
N\A |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome |
Rejected |
Alogliptin |
3 |
SYR-322_402 |
N\A |
